Pfizer Inc Joins the Spiral Tower as a Tenant
Discover Pfizer Inc's new tenant status in the Spiral Tower, a key move in corporate real estate. Explore what this means for the iconic NYC building.
Topic
Pfizer
A collection of 20 issues
The Spiral Welcomes Pfizer and Debevoise & Plimpton as New Tenants
The Spiral secures leases with five prominent tenants, including Pfizer Inc and Debevoise & Plimpton LLP, enhancing its commercial appeal.
Pfizer Faces Challenges Amid Healthcare Sector Sell-Off
Explore how Pfizer navigates the broader healthcare sector challenges and market sell-off, impacting operations and future strategies.
Sangamo Shares Plummet as Pfizer Ends Partnership
Sangamo Therapeutics stock drops 50% following Pfizer's termination of their co-development agreement. Discover the impact on Sangamo's future prospects.
Sangamo Shares Plummet After Pfizer Exit
Sangamo Therapeutics shares plunged 50% as Pfizer ends collaboration on hemophilia drug, impacting biotech stocks. Discover the implications for investors.
Pfizer Shares Rise Amid Sangamo Partnership Termination
Pfizer shares slightly increased despite ending its collaboration with Sangamo. Explore what this means for investors and the future of biotech cooperation.
Sangamo Shares Plunge as Pfizer Exits Partnership
Sangamo Therapeutics' stock plummeted by over 50% following Pfizer's decision to withdraw from their joint agreement. Explore the impact on biotech stocks.
Pfizer Shares Rise Despite Agreement Termination
Pfizer shares saw a slight uptick in trading despite the recent termination of an agreement. Explore the resilience of Pfizer's stock in fluctuating markets.
Sangamo Shares Plummet After Pfizer Ends Collaboration
Sangamo Therapeutics' stock nosedives over 50% as Pfizer halts partnership on hemophilia drug. Discover the implications for Sangamo's future and investor concerns.
Sangamo Reclaims Rights to Hemophilia Gene Therapy from Pfizer
Sangamo Therapeutics regains rights to giroctocogene fitelparvovec after Pfizer's successful Phase 3 trials, marking a pivotal shift in hemophilia gene therapy.